Royalty Pharma partners with J&J on $500M drug development deal
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/24/2026
- Wall St slips as Middle East escalations lifts oil; Trump-Xi talks in focus
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oil gains on little sign of progress in US-Iran talks
- S&P 500 history shows strong gains across Fed hiking cycles: BCA
- JPMorgan upgrades CoreWeave on stronger compute pricing
- Plug Power COO resigns to join another company
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Wall Street ends down as oil prices, Treasury yields rise
Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases
March 30, 2026 7:15 AM EDTNEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced a research and development (R&D) co-funding agreement with Johnson & Johnson for a total of $500 million in 2026 and 2027 to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases.
JNJ4804 is a novel coantibody therapy that blocks the complementary interleukin23 (IL23) and tumor necrosis factor (TNF) pathways, delivering synergistic effects on the pathogenesis of chronic immunemediated diseases.
We are delighted to collaborate with Johnson & Johnson on the clinical development of JNJ-4804, said Pablo Legorreta, Chief... More
